Search Results
May 08, 2026, 06:40 ET The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
MSD's[1] anti-PD-1 monoclonal antibody pembrolizumab (KEYTRUDA®[2]) as first‑line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have PD-L1 tumor proportion score (TPS) ≥1% and
More news about: Kelun-Biotech
May 07, 2026, 16:06 ET Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Keynote-522, the standard neoadjuvant treatment for TNBC includes systemic chemotherapy (anthracyclines, cyclophosphamide, paclitaxel, carboplatin) and the anti-PD-1 monoclonal antibody pembrolizumab. pCR rates range from 50 to 65%, depending on tumor size. Rates are generally lower in the larger-sized tumors or
More news about: Intensity Therapeutics Inc.
May 07, 2026, 13:11 ET PAN GLOBAL SIGNALE LA PRÉSENCE D'OR À HAUTE TENEUR EN SURFACE (20,2 g/t) SUR 5,0 MÈTRES DANS LE CADRE DU PROJET CÁRMENES, EN ESPAGNE
PtPdNombre
More news about: Pan Global Resources Inc.
May 07, 2026, 10:09 ET Greenland Mines Just Reported PdEq Grades Up 45-55% in MetalPrice Sensitivity Work at One of the World's Largest Undeveloped Pd-Au-Pt Deposits
Low case: $1,725/oz Pd, $3,000/oz Au, $2,100/oz PtMedium case: $1,725/oz Pd, $3,500/oz Au, $2,100/oz PtHigh case: $1,800/oz Pd, $5,000/oz Au, $2,175/oz PtThe 2022 base case had used $1,725/oz Pd, $1,800/oz Au, and $1,250/oz Pt. SLR considers
More news about: Equity Insider
May 07, 2026, 10:00 ET Solution Tree Celebrates 2026 California Distinguished Schools
Global PD Teams and
More news about: Solution Tree
May 07, 2026, 08:30 ET Greenland Mines Reports Up To 45% - 55% Increase in Palladium Equivalent (PdEq) Grades at Skaergaard in Sensitivity Study
case assumes metal prices of US$1,725/oz Pd, US$3,000/oz Au, and US$2,100/oz Pt.Medium sensitivity case assumes metal prices of US$1,725/oz Pd, US$3,500/oz Au, and US$2,100/oz Pt.High sensitivity case assumes metal prices of US$1,800/oz Pd, US$5,000/oz Au, and US$2,175/oz Pt.Bulk
More news about: Greenland Mines Ltd
May 07, 2026, 08:00 ET Repertoire Immune Medicines Announces FDA Fast Track Designation for its Investigational Immune Medicine, RPTR-1-201
cell-targeted immune medicines.RPTR-1-201 is currently being evaluated in a Phase 1/2 clinical trial as monotherapy and in combination with an anti-PD-1 therapy in participants with advanced solid tumors (ClinicalTrials.gov Identifier: NCT07293754). Repertoire plans to discuss development options in
More news about: Repertoire Immune Medicines
May 07, 2026, 07:36 ET PAN GLOBAL CONFIRMA ALTA LEY EN SUPERFICIE CON 5,0 METROS A 20,2 g/t DE ORO EN EL PROYECTO CÁRMENES
PtPdmuestra
More news about: Pan Global Resources Inc.
May 07, 2026, 07:27 ET PAN GLOBAL REPORTS SURFACE HIGH-GRADE GOLD WITH 20.2 g/t OVER 5.0 METERS AT CÁRMENES PROJECT, SPAIN
PtPdNumber
More news about: Pan Global Resources Inc.
May 07, 2026, 07:27 ET PAN GLOBAL REPORTS SURFACE HIGH-GRADE GOLD WITH 20.2 g/t OVER 5.0 METERS AT CÁRMENES PROJECT, SPAIN
PtPdNumber
More news about: Pan Global Resources Inc.
May 06, 2026, 08:06 ET Bradley's Elvari® Washroom Accessories Collection Wins Red Dot Product Design Award 2026
red-dot.org/pd.About Bradley CompanyFor more than 100 years, Bradley Company has been a leader in advanced commercial washrooms and comprehensive
More news about: Bradley Company
May 06, 2026, 05:27 ET American Parkinson Disease Association Launches One-of-a-Kind Card Game to Help People with Parkinson's Build Intimacy and Connection
one-of-a-kind resource for people living with Parkinson's disease (PD): ParkinSex: The Game. This unique offering was designed to help address the challenges couples can face with physical and emotional intimacy when navigating life with PD. ParkinSex: The Game is available for free for the Parkinson's
More news about: American Parkinson Disease Association, Inc.
May 06, 2026, 02:30 ET Lion Zone Delivers Second Best Intersection Ever As Power Metallic intercepts 22.00 Meters of 11.46% CuEqRec¹ in Hole 26-095
CuPdPt
More news about: Power Metallic Mines Inc.
May 05, 2026, 16:05 ET Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
as the HER2-targeted agent of choice in HER2+ 1L advanced gastroesophageal adenocarcinoma (GEA); additional benefit from tislelizumab irrespective of PD-L1 status.Supplemental Biologics License Application (sBLA) accepted by FDA under Real-Time Oncology Review (RTOR) program with potential approval
More news about: Jazz Pharmaceuticals plc
May 05, 2026, 16:05 ET Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
as the HER2-targeted agent of choice in HER2+ 1L advanced gastroesophageal adenocarcinoma (GEA); additional benefit from tislelizumab irrespective of PD-L1 status.Supplemental Biologics License Application (sBLA) accepted by FDA under Real-Time Oncology Review (RTOR) program with potential approval
More news about: Jazz Pharmaceuticals plc
May 05, 2026, 11:08 ET Altura Expands Contract with The Michael J. Fox Foundation to Broaden Access to Parkinson's Research Opportunities
American Connections to Parkinson's Disease (BLAAC PD) study is an initiative of the Global Parkinson's Genetics Program (GP2), a resource program of the Aligning Science Across Parkinson's (ASAP) initiative. MJFF supports implementation of BLAAC PD (
More news about: Altura
May 05, 2026, 10:05 ET Creatv Announces Five Clinical Data Presentations at ASCO 2026
Monitoring PD-L1 expression in circulating cancer associated cells for prediction of clinical outcomes in metastatic breast cancer patients treated with immune checkpoint
More news about: Creatv MicroTech, Inc.
May 05, 2026, 06:00 ET IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
agreement with AstraZeneca plc to evaluate the efficacy and safety of IDE849 in combination with Imfinzi® (durvalumab), a programmed death-ligand 1 (PD-L1) inhibitor, in extensive-stage SCLC. IDEAYA will sponsor the clinical combination trial; AstraZeneca will supply Imfinzi® at no cost.Achieved
More news about: IDEAYA Biosciences, Inc.
May 05, 2026, 03:40 ET Senhwa Biosciences Launches Global Study, Targeting Breakthrough in Hard-to-Treat Cancers with CX-5461 and Tislelizumab Combination
The study will evaluate Senhwa's first-in-class investigational drug, Pidnarulex (CX-5461), in combination with BeOne Medicines' marketed PD-1 inhibitor, tislelizumab, across multiple advanced or metastatic solid tumors, including pancreatic cancer, colorectal cancer, and melanoma—areas with
More news about: Senhwa Biosciences, Inc.
May 04, 2026, 07:00 ET Compugen to Release First Quarter 2026 Results on Monday, May 18, 2026
therapeutic anti-TIGIT antibody, have been evaluated for the treatment of solid tumors as monotherapy and in combinations of dual (PVRIG/PD-1, PVRIG/TIGIT) and triple (PVRIG/PD-1/TIGIT) blockade. Currently, the only clinical trial we sponsor and are conducting is a blinded randomized ovarian cancer platform
More news about: Compugen Ltd.
May 04, 2026, 02:30 ET Power Metallic intercepts 17.45 Meters of 9.47% CuEqRec¹ in Hole 26-094 and 39 Meters of 5.66% CuEqRec¹ in Hole 26-101 at Lion
CuPdPt
More news about: Power Metallic Mines Inc.
May 01, 2026, 00:23 ET Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
cohort.1.Title: Bispecific Trap-Antibody Inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101): Clinical PK/PD Cohort in Asian Patients with Macular Edema Secondary to Inflammation (MESI)Poster Session: Clinical features and treatment outcomes in
More news about: Kodiak Sciences Inc.
Apr 30, 2026, 19:02 ET /C O R R E C T I O N -- Amgen/
DeLLphi-303, a Phase 1b study of IMDELLTRA in combination with a programmed cell death protein ligand-1 (PD-L1) inhibitor, carboplatin and etoposide or separately in combination with a PD-L1 inhibitor alone, is ongoing in patients with first-line ES-SCLC.DeLLphi-305, a Phase 3 study of IMDELLTRA
More news about: Amgen
Apr 30, 2026, 10:54 ET Legal-Bay Pre-Settlement Funding Now Accepting Applications for Paraquat Lawsuit Funding as Litigation Surges Nationwide
decisions within 24–48 hours. Applicants are assessed based on key factors such as documented exposure history, medical diagnosis of Parkinson's disease or PD, and overall case strength.Individuals diagnosed with Parkinson's disease who believe they were exposed to paraquat are encouraged to explore their
More news about: Legal-Bay, LLC
Apr 30, 2026, 08:00 ET Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer
Patent Office (ILPO) has granted Genprex a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies for the treatment of cancer.
More news about: Genprex, Inc.